137 related articles for article (PubMed ID: 10860353)
1. [Influence of the radioactive strontium (89Sr) using for nuclear medical radiation therapy upon radioactive draining-water system].
Narita Y; Hatano K; Kinoshita F; Togawa T; Yui N; Endo K; Koizumi M
Kaku Igaku; 2000 May; 37(3):227-36. PubMed ID: 10860353
[TBL] [Abstract][Full Text] [Related]
2. [Investigation of radiation safety management of nuclear medicine facilities in Japan; contamination of radioactivity in the draining-water system. A Working Group of Japanese Society of Nuclear Medicine for the Guidelines of Nuclear Medicine Therapy].
Endo K; Koizumi M; Kinoshita F; Nakazawa K
Kaku Igaku; 1999 Dec; 36(9):1023-31. PubMed ID: 10659587
[TBL] [Abstract][Full Text] [Related]
3. Strontium 89 therapy for the palliation of pain due to osseous metastases.
Robinson RG; Preston DF; Schiefelbein M; Baxter KG
JAMA; 1995 Aug; 274(5):420-4. PubMed ID: 7542352
[TBL] [Abstract][Full Text] [Related]
4. [Drawing up the guidelines for ventilation, draining and disposal of radioactive medical waste].
Koizumi M; Endo K; Yokoyama K; Narita Y; Kinoshita F; Hosono M; Kusakabe K; Kosaka N; Mori Y; Kosuda S
Kaku Igaku; 2004 Feb; 41(1):48-50. PubMed ID: 15171458
[No Abstract] [Full Text] [Related]
5. Systemic radionuclide therapy in pain palliation.
Liepe K; Runge R; Kotzerke J
Am J Hosp Palliat Care; 2005; 22(6):457-64. PubMed ID: 16323716
[TBL] [Abstract][Full Text] [Related]
6. [Development of a simple quantitative method for the strontium-89 concentration of radioactive liquid waste using the plastic scintillation survey meter for beta rays].
Narita H; Tsuchiya Y; Hirase K; Uchiyama M; Fukushi M
Kaku Igaku; 2012 Nov; 49(4):351-5. PubMed ID: 23402205
[TBL] [Abstract][Full Text] [Related]
7. Use of strontium-89 in endocrine-refractory prostate cancer metastatic to bone. Provincial Genitourinary Cancer Disease Site Group.
Brundage MD; Crook JM; Lukka H
Cancer Prev Control; 1998 Apr; 2(2):79-87. PubMed ID: 9765768
[TBL] [Abstract][Full Text] [Related]
8. [A questionnaire about radiation safety management of the draining-water system at nuclear medicine facilities].
Shizukuishi K; Watanabe H; Narita H; Kanaya S; Kobayashi K; Yamamoto T; Tsukada M; Iwanaga T; Ikebuchi S; Kusama K; Tanaka M; Namiki N; Fuiimura Y; Horikoshi A; Inoue T; Kusakabe K; ;
Kaku Igaku; 2004 May; 41(2):109-21. PubMed ID: 15354724
[TBL] [Abstract][Full Text] [Related]
9. [Possibilities of systemic radiotherapy with high-purity 89Sr chloride in the treatment of bone metastases].
Fomin DK; Tararukhina OB; Nazarov AA
Vestn Rentgenol Radiol; 2012; (2):29-31. PubMed ID: 22730757
[TBL] [Abstract][Full Text] [Related]
10. 85Sr contaminant as a reliable tracer of 89Sr for monitoring urinary radioactivity in patients treated with 89Sr for bone metastases.
De Agostini A; Mascaro L; Pizzocaro C; Panarotto MB; Bestagno M
J Nucl Biol Med (1991); 1993 Mar; 37(1):38-44. PubMed ID: 7687149
[TBL] [Abstract][Full Text] [Related]
11. [89Sr Therapy for pain relief in patients with bone metastases].
Koizumi K; Arbab AS; Toyama K; Shirasu M; Osawa S; Araki T; Yamaguchi M; Onishi H; Araki T; Arai T; Komatsu H; Ueno A; Nokata H
Kaku Igaku; 1996 Nov; 33(11):1243-8. PubMed ID: 8986064
[TBL] [Abstract][Full Text] [Related]
12. [Pain control for bone metastasis using radioactive strontium].
Yamaguchi K
Gan To Kagaku Ryoho; 2010 Oct; 37(10):1868-71. PubMed ID: 20948249
[TBL] [Abstract][Full Text] [Related]
13. Relative efficacy of 32P and 89Sr in palliation in skeletal metastases.
Nair N
J Nucl Med; 1999 Feb; 40(2):256-61. PubMed ID: 10025832
[TBL] [Abstract][Full Text] [Related]
14. Bone pain palliation with strontium-89 in cancer patients with bone metastases.
Giammarile F; Mognetti T; Resche I
Q J Nucl Med; 2001 Mar; 45(1):78-83. PubMed ID: 11456379
[TBL] [Abstract][Full Text] [Related]
15. Decreased serum E-selectin concentration after 89Sr-chloride therapy for metastatic prostate cancer bone pain.
Papatheofanis FJ
J Nucl Med; 2000 Jun; 41(6):1021-4. PubMed ID: 10855628
[TBL] [Abstract][Full Text] [Related]
16. Considerations in the selection of radiopharmaceuticals for palliation of bone pain from metastatic osseous lesions.
Bouchet LG; Bolch WE; Goddu SM; Howell RW; Rao DV
J Nucl Med; 2000 Apr; 41(4):682-7. PubMed ID: 10768569
[TBL] [Abstract][Full Text] [Related]
17. [Radioprotection and environmental pollution by the use of the radionuclides 89Sr, 186Re, and 153Sm for pain palliation in metastatic bone diseases. Related calculations].
Sbonias E
Hell J Nucl Med; 2005; 8(2):68-73. PubMed ID: 16142246
[TBL] [Abstract][Full Text] [Related]
18. [The efficacy of therapy using 89Sr-strontium chloride in 200 patients with bone metastases of a prostatic cancer].
Haesner M; Buchali K; Pink V; Lips H
Nuklearmedizin; 1992 Mar; 31(2):48-52. PubMed ID: 1373485
[TBL] [Abstract][Full Text] [Related]
19. Dose estimation in strontium-89 radiotherapy of metastatic prostatic carcinoma.
Breen SL; Powe JE; Porter AT
J Nucl Med; 1992 Jul; 33(7):1316-23. PubMed ID: 1613572
[TBL] [Abstract][Full Text] [Related]
20. Quantitation of biochemical markers of bone resorption following strontium-89-chloride therapy for metastatic prostatic carcinoma.
Papatheofanis FJ
J Nucl Med; 1997 Aug; 38(8):1175-9. PubMed ID: 9255144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
